Paracelsus Medizinische Privatuniversität (PMU)

Research & Innovation
Publications

Lenvatinib or Regorafenib in combination with Cdk5 inhibition – new promising therapeutic approaches for treating HCC patients

#2022

PMU Author
Petra Huber-Cantonati

All Authors
Petra Huber-Cantonati, T. Mähr, MA Ardelt, J. Pachmayr

Abstract

We are sorry. The full text is not available.